Is Ozempic really only for diabetic patients? Not exactly

What did @thisis_nami actually say?

Honestly, not much that's medically analyzable. The transcript from this video is entirely song lyrics, specifically something along the lines of "Oh Darkness in dust, glide, yeah, shadow, thought, dancing, now, asking for my hand." There are no spoken health claims here. The message lives entirely in the caption, which reads: "0zempic is for diabetic people.. don't misuse it."

So we're fact-checking a caption, not a medical monologue. The creator seems to be pushing back against the wave of non-diabetic people using semaglutide (Ozempic) for weight loss, which is a fair concern to raise. But the framing, that Ozempic is exclusively for diabetic people, is where things get medically complicated.

Does the science back this up?

Partially, but the FDA approvals tell a more nuanced story. Semaglutide is approved under two brand names for two different indications, and conflating them misses something important.

Ozempic (semaglutide 0.5 mg, 1 mg, 2 mg) is FDA-approved specifically for type 2 diabetes management and cardiovascular risk reduction in adults with type 2 diabetes and established heart disease. That part of the caption holds up. Wegovy (semaglutide 2.4 mg) received FDA approval in 2021 for chronic weight management in adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with at least one weight-related condition, no diabetes diagnosis required.

The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) enrolled adults without diabetes and found semaglutide 2.4 mg produced an average 14.9% body weight reduction versus 2.4% with placebo. Obesity is a recognized chronic disease. Treating it is not inherently misuse.

What did they get wrong (or right)?

They got one thing right and one thing meaningfully wrong. Right: using Ozempic specifically, the diabetes-formulated product, without a legitimate clinical indication does raise real supply, safety, and ethical concerns. Shortages have affected type 2 diabetes patients who depend on the medication. That's a documented public health problem worth calling out.

Wrong: framing GLP-1 receptor agonist therapy as categorically inappropriate for non-diabetic people ignores FDA-approved indications. Wegovy is the same molecule as Ozempic, semaglutide, approved for obesity in people without diabetes. Davies et al. (2021, Diabetes Care) confirmed semaglutide's efficacy across metabolic profiles, including in patients without type 2 diabetes. The American Obesity Association and multiple endocrinology guidelines now treat obesity as a chronic disease requiring pharmacological intervention in appropriate patients.

The distinction between brand-name products matters here. Ozempic is not Wegovy, even though both contain semaglutide. Dose, indication, and prescribing context are different. Blurring that line in a public-facing caption contributes to the same confusion the creator is trying to correct.

What should you actually know?

If you're seeing GLP-1 content on TikTok and trying to figure out what applies to you, here's the core of it. Semaglutide exists in multiple formulations with different approved uses. Ozempic is for type 2 diabetes. Wegovy is for obesity management. A physician or regulated telehealth provider should assess which, if any, is appropriate based on your individual health profile.

The concern about drug shortages is legitimate. The FDA reported Ozempic and Wegovy supply disruptions throughout 2022 and 2023, partly driven by off-label demand. Patients with type 2 diabetes losing access to their medication because of off-label prescribing is a real harm.

At the same time, gatekeeping GLP-1 therapy from people with obesity who have a valid prescription and clinical indication is also a harm. The conversation is more complicated than "diabetics only." Anyone navigating this decision should be working with a licensed provider, not drawing conclusions from a TikTok caption, including this one.